Intermittent LHRH therapy in the management of castrate-resistant prostate cancer (CRPCa):results of a multi-institutional randomized prospective clinical trial

Organ, Michael, Wood, Lori, Wilke, Derek, Skedgel, Chris ORCID: https://orcid.org/0000-0003-4989-8846, Cheng, Tina, North, Scott, Thompson, Kara, Winch, Susan and Rendon, Ricardo (2013) Intermittent LHRH therapy in the management of castrate-resistant prostate cancer (CRPCa):results of a multi-institutional randomized prospective clinical trial. American Journal of Clinical Oncology, 36 (6). pp. 601-605. ISSN 1537-453X

Full text not available from this repository. (Request a copy)

Abstract

Patients who develop castration-resistant prostate cancer (CRPCa) typically continue on androgen deprivation therapy (ADT). Whether these patients need to remain on ADT has not been well studied. We conducted a multicenter randomized trial to compare an intermittent versus continuous approach to ADT in CRPCa patients. Overall survival, health-related quality of life (QOL), and cost were the main endpoints.

Item Type: Article
Uncontrolled Keywords: aged,aged, 80 and over,costs and cost analysis,follow-up studies,gonadotropin-releasing hormone,humans,male,middle aged,prostate-specific antigen,prostatic neoplasms, castration-resistant,quality of life,questionnaires,testosterone,treatment outcome,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 03 Feb 2015 13:04
Last Modified: 30 Sep 2022 00:48
URI: https://ueaeprints.uea.ac.uk/id/eprint/51928
DOI: 10.1097/COC.0b013e31825d5664

Actions (login required)

View Item View Item